cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Stockal+Disclaimer.pdf
24 own
13 watching
Current Price
$9.78
$0.36
(3.82%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,274.01M
52-Week High
52-Week High
16.74500
52-Week Low
52-Week Low
4.97000
Average Volume
Average Volume
3.36M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,274.01M
icon52-Week High16.74500
icon52-Week Low4.97000
iconAverage Volume3.36M
iconDividend Yield--
iconP/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
11 months ago
Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem From left: Jordan Christensen, SVP of Technology and Toronto Site Head of Recursion; Honourable Doug Ford, Premier of Ontario; Chris Gibson, Co-Founder and CEO of Recursion; ...
Zolmax
1 year ago
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX Get Rating) CEO Christopher Gibson sold 70,890 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, March 8th. The stock was sold at an average price of $8.10, for a total transaction of $574,209.00. Following the sale, ...
Globe Newswire
1 year ago
SALT LAKE CITY, March 01, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Morgan Stanley Technology, Media & Telecom ...
Globe Newswire
1 year ago
Salt Lake City, Utah, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rare Disease advocacy organizations and biotech and healthcare industry leaders will partner to accelerate the diagnosis and improve the care of more than 344,000 Utahns living with a rare disease. On Rare Disease Day, Feb. 28, 2023, community ...
PR Newswire
1 year ago
Recursion to Participate in Upcoming Investor Conferences Recursion to Participate in Upcoming Investor Conferences PR Newswire SALT LAKE CITY, Dec. 20, 2022 SALT LAKE CITY, Dec. 20, 2022 /PRNewswire/ --Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$9.78
$0.36
(3.82%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00